NCT00509782View on ClinicalTrials.gov

Phase I Trial of ZIO-101 in Patients With Solid Tumors

PHASE1CompletedINTERVENTIONAL

Enrollment

47

Participants

Timeline

Start Date

May 31, 2005

Primary Completion Date

April 30, 2008

Study Completion Date

April 30, 2008

Conditions

Solid Tumors

Interventions

DRUG

ZIO-101

Starting Dose 78 mg/m\^2 intravenously daily for 5 consecutive days repeated every 4 weeks.

Trial Locations (1)

77030

U.T.M.D. Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Alaunos Therapeutics

All Listed Sponsors

collaborator

Alaunos Therapeutics

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT00509782 - Phase I Trial of ZIO-101 in Patients With Solid Tumors | Biotech Hunter | Biotech Hunter